Oxygen Supply-Demand Imbalance may be tied to Type 2 Myocardial Infarction

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-07-15 04:15 GMT   |   Update On 2022-07-15 04:15 GMT

To evaluate the prevalence and outcomes of different factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction, researchers conducted a secondary analysis of the High-STEACS cluster-randomized clinical trial. They conducted the trial at 10 secondary and tertiary care hospitals including a total of 6096 patients with a diagnosis of type 1...

Login or Register to read the full article

To evaluate the prevalence and outcomes of different factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction, researchers conducted a secondary analysis of the High-STEACS cluster-randomized clinical trial.

They conducted the trial at 10 secondary and tertiary care hospitals including a total of 6096 patients with a diagnosis of type 1 or type 2 myocardial infarction.

The main outcome was all-cause death at 1 year according to the factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction.

In this secondary analysis of a randomized clinical trial, mortality after type 2 myocardial infarction was associated with the underlying etiologic factor associated with oxygen supply-demand imbalance. Most type 2 myocardial infarctions were associated with tachyarrhythmia, with a better prognosis, whereas hypoxemia and anemia accounted for one-third of cases, with double the mortality of type 1 myocardial infarction.

The researchers hence noted that these differential outcomes should be considered by clinicians when determining which cases need to be managed if patient outcomes are to improve.

Reference:

Bularga A, Taggart C, Mendusic F, et al. Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial. JAMA Network Open. 2022;5(7):e2220162. doi:10.1001/jamanetworkopen.2022.20162

Tags:    
Article Source : JAMA Network Open

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News